Related by context. Frequent words. (Click for all words.) 62 Pivotal Phase III 62 Phase Ib clinical 61 Acute Myocardial Infarction 61 Multicenter 61 TRITON TIMI 61 PRECiSE 59 ACRIN 59 elotuzumab 59 Randomized controlled 59 Gynecologic Oncology Group 58 relapsing multiple sclerosis 58 HER2 positive metastatic breast 58 Pivotal Phase 58 placebo controlled clinical 58 placebo controlled Phase 58 NSABP 58 Heart Failure Patients 58 Percutaneous Coronary Intervention 57 SWOG 57 Pharmacokinetic 57 Antihypertensive 57 heavily pretreated 57 Chronic Heart Failure 57 subanalysis 57 placebo controlled clinical trials 57 Arch Neurol 57 MADIT CRT 57 Patient Registry 57 KRN# 57 Ischemic 57 prospective observational 57 SPIRIT III 57 Radiation Therapy Oncology 56 Clinical Trial Results 56 phase IIb clinical 56 Pulmonary Arterial Hypertension 56 randomized Phase III 56 prospectively defined 56 secondary efficacy endpoints 56 multicenter clinical 56 Fibrillex TM 56 Arch Intern Med 56 Diabetic Macular Edema 56 Gemzar ® 56 metastatic castration resistant 56 Cardiovascular Risk 56 ALLHAT 56 SPIRIT IV 56 Amrubicin 56 Systematic Review 56 subgroup analyzes 56 Thrombolysis 56 Rosuvastatin 56 Pivotal Trial 56 substudy 56 multicenter randomized double 56 Apixaban 56 Meta Analysis 55 GSK# [001] 55 Phase 1b clinical 55 Phase III randomized 55 Myocardial Infarction 55 J Am Coll 55 phase IIa 55 Presents Positive 55 Prostate Cancer Patients 55 pharmacokinetic PK 55 ACZ# 55 Solid Tumors 55 abiraterone acetate 55 randomized controlled clinical 55 active comparator 55 Phase III Clinical Trial 55 J Clin Endocrinol Metab 55 RTOG 55 Completes Enrollment 55 SABCS 55 Metastatic Melanoma 55 pertuzumab 55 J Clin Oncol 55 Hepatitis C Virus 55 ximelagatran 54 axitinib 54 #:#-# [031] 54 PROPEL 54 acute coronary syndromes ACS 54 nonrandomized 54 CR# vcMMAE 54 placebo controlled studies 54 ATTAIN 54 multicenter randomized 54 Phase 1b trial 54 phase IIb 54 angiotensin converting enzyme inhibitors 54 myocardial infarctions 54 multicenter Phase 54 liver transplant recipients 53 Chronic Hepatitis C 53 tolvaptan 53 placebo controlled trials 53 NYHA Class II